Illumina, Inc. (0J8Z.L)
USD 74.54
(1.41%)
USD 74.54
(1.41%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -1.16 Billion USD | 73.64% |
| 2022 | -4.4 Billion USD | -677.95% |
| 2021 | 762 Million USD | 16.16% |
| 2020 | 656 Million USD | -34.53% |
| 2019 | 1 Billion USD | 21.31% |
| 2018 | 826 Million USD | 13.77% |
| 2017 | 726 Million USD | 56.92% |
| 2016 | 462.64 Million USD | 0.24% |
| 2015 | 461.55 Million USD | 30.62% |
| 2014 | 353.35 Million USD | 181.99% |
| 2013 | 125.3 Million USD | -17.15% |
| 2012 | 151.25 Million USD | 74.6% |
| 2011 | 86.62 Million USD | -30.64% |
| 2010 | 124.89 Million USD | 72.79% |
| 2009 | 72.28 Million USD | 43.2% |
| 2008 | 50.47 Million USD | 118.13% |
| 2007 | -278.35 Million USD | -796.45% |
| 2006 | 39.96 Million USD | 291.47% |
| 2005 | -20.87 Million USD | -235.33% |
| 2004 | -6.22 Million USD | 77.0% |
| 2003 | -27.06 Million USD | 32.9% |
| 2002 | -40.33 Million USD | -62.47% |
| 2001 | -24.82 Million USD | -33.41% |
| 2000 | -18.6 Million USD | -237.22% |
| 1999 | -5.51 Million USD | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q2 | -1.98 Billion USD | -1477.78% |
| 2024 Q3 | 705 Million USD | 135.46% |
| 2024 Q1 | -126 Million USD | 28.41% |
| 2023 Q4 | -176 Million USD | 76.66% |
| 2023 FY | -1.16 Billion USD | 73.64% |
| 2023 Q1 | 3 Million USD | 102.14% |
| 2023 Q2 | -234 Million USD | -7900.0% |
| 2023 Q3 | -754 Million USD | -222.22% |
| 2022 Q4 | -140 Million USD | 96.33% |
| 2022 FY | -4.4 Billion USD | -677.95% |
| 2022 Q1 | 86 Million USD | -23.21% |
| 2022 Q2 | -535 Million USD | -722.09% |
| 2022 Q3 | -3.81 Billion USD | -613.27% |
| 2021 Q3 | 317 Million USD | 71.35% |
| 2021 Q4 | 112 Million USD | -64.67% |
| 2021 FY | 762 Million USD | 16.16% |
| 2021 Q1 | 147 Million USD | -42.8% |
| 2021 Q2 | 185 Million USD | 25.85% |
| 2020 Q3 | 179 Million USD | 280.85% |
| 2020 Q4 | 257 Million USD | 43.58% |
| 2020 Q1 | 173 Million USD | -27.62% |
| 2020 Q2 | 47 Million USD | -72.83% |
| 2020 FY | 656 Million USD | -34.53% |
| 2019 Q4 | 239 Million USD | 2.14% |
| 2019 FY | 1 Billion USD | 21.31% |
| 2019 Q3 | 234 Million USD | -20.95% |
| 2019 Q2 | 296 Million USD | 27.04% |
| 2019 Q1 | 233 Million USD | 10.95% |
| 2018 Q4 | 210 Million USD | 5.53% |
| 2018 Q3 | 199 Million USD | -4.78% |
| 2018 FY | 826 Million USD | 13.77% |
| 2018 Q1 | 208 Million USD | 205.88% |
| 2018 Q2 | 209 Million USD | 0.48% |
| 2017 Q1 | 373 Million USD | 201.38% |
| 2017 Q3 | 163 Million USD | 27.34% |
| 2017 Q4 | 68 Million USD | -58.28% |
| 2017 FY | 726 Million USD | 56.92% |
| 2017 Q2 | 128 Million USD | -65.68% |
| 2016 Q1 | 89.58 Million USD | -14.25% |
| 2016 Q2 | 120.41 Million USD | 34.41% |
| 2016 FY | 462.64 Million USD | 0.24% |
| 2016 Q3 | 128.88 Million USD | 7.04% |
| 2016 Q4 | 123.76 Million USD | -3.98% |
| 2015 FY | 461.55 Million USD | 30.62% |
| 2015 Q3 | 118.17 Million USD | 15.58% |
| 2015 Q4 | 104.47 Million USD | -11.59% |
| 2015 Q1 | 136.65 Million USD | -10.84% |
| 2015 Q2 | 102.24 Million USD | -25.18% |
| 2014 Q1 | 59.97 Million USD | -25.64% |
| 2014 Q2 | 46.6 Million USD | -22.3% |
| 2014 Q3 | 93.48 Million USD | 100.6% |
| 2014 FY | 353.35 Million USD | 181.99% |
| 2014 Q4 | 153.28 Million USD | 63.96% |
| 2013 Q1 | -22.58 Million USD | -131.41% |
| 2013 Q3 | 31.35 Million USD | -12.6% |
| 2013 Q4 | 80.66 Million USD | 157.23% |
| 2013 FY | 125.3 Million USD | -17.15% |
| 2013 Q2 | 35.87 Million USD | 258.84% |
| 2012 FY | 151.25 Million USD | 74.6% |
| 2012 Q4 | 71.9 Million USD | 141.71% |
| 2012 Q1 | 26.2 Million USD | 123.57% |
| 2012 Q3 | 29.74 Million USD | 27.12% |
| 2012 Q2 | 23.4 Million USD | -10.69% |
| 2011 Q2 | 30.62 Million USD | 26.86% |
| 2011 Q4 | 11.72 Million USD | -41.84% |
| 2011 FY | 86.62 Million USD | -30.64% |
| 2011 Q3 | 20.15 Million USD | -34.19% |
| 2011 Q1 | 24.13 Million USD | -37.21% |
| 2010 Q2 | 29.79 Million USD | 40.49% |
| 2010 Q3 | 35.44 Million USD | 18.97% |
| 2010 Q4 | 38.44 Million USD | 8.44% |
| 2010 FY | 124.89 Million USD | 72.79% |
| 2010 Q1 | 21.2 Million USD | 81.19% |
| 2009 Q4 | 11.7 Million USD | -31.46% |
| 2009 Q2 | 24.68 Million USD | 31.24% |
| 2009 Q1 | 18.81 Million USD | -35.0% |
| 2009 FY | 72.28 Million USD | 43.2% |
| 2009 Q3 | 17.07 Million USD | -30.83% |
| 2008 Q4 | 28.93 Million USD | 497.08% |
| 2008 Q2 | 15.39 Million USD | 14.67% |
| 2008 Q3 | -7.28 Million USD | -147.33% |
| 2008 FY | 50.47 Million USD | 118.13% |
| 2008 Q1 | 13.42 Million USD | 431.72% |
| 2007 Q4 | -4.04 Million USD | -127.91% |
| 2007 Q3 | 14.5 Million USD | 56.55% |
| 2007 Q2 | 9.26 Million USD | 103.11% |
| 2007 FY | -278.35 Million USD | -796.45% |
| 2007 Q1 | -298.07 Million USD | -1838.86% |
| 2006 Q3 | 16.16 Million USD | 138.8% |
| 2006 FY | 39.96 Million USD | 291.47% |
| 2006 Q4 | 17.14 Million USD | 6.06% |
| 2006 Q2 | 6.76 Million USD | 6607.69% |
| 2006 Q1 | -104 Thousand USD | -131.9% |
| 2005 Q1 | -1.23 Million USD | -118.96% |
| 2005 Q2 | -18.53 Million USD | -1401.13% |
| 2005 Q3 | -1.42 Million USD | 92.31% |
| 2005 Q4 | 326 Thousand USD | 122.86% |
| 2005 FY | -20.87 Million USD | -235.33% |
| 2004 Q2 | -3.51 Million USD | 18.4% |
| 2004 Q4 | 6.51 Million USD | 421.57% |
| 2004 Q3 | -2.02 Million USD | 42.38% |
| 2004 Q1 | -4.3 Million USD | 1.58% |
| 2004 FY | -6.22 Million USD | 77.0% |
| 2003 Q3 | -5.51 Million USD | 38.56% |
| 2003 Q4 | -4.37 Million USD | 20.56% |
| 2003 FY | -27.06 Million USD | 32.9% |
| 2003 Q1 | -9.33 Million USD | -16.73% |
| 2003 Q2 | -8.97 Million USD | 3.94% |
| 2002 Q3 | -7.6 Million USD | 76.13% |
| 2002 FY | -40.33 Million USD | -62.47% |
| 2002 Q2 | -31.84 Million USD | -267.45% |
| 2002 Q1 | -8.66 Million USD | -5.35% |
| 2002 Q4 | -8 Million USD | -5.24% |
| 2001 Q1 | -4.91 Million USD | -6.53% |
| 2001 FY | -24.82 Million USD | -33.41% |
| 2001 Q4 | -8.22 Million USD | -42.22% |
| 2001 Q3 | -5.78 Million USD | 1.83% |
| 2001 Q2 | -5.89 Million USD | -19.82% |
| 2000 FY | -18.6 Million USD | -237.22% |
| 2000 Q3 | -3.87 Million USD | 26.47% |
| 2000 Q1 | -4.84 Million USD | 0.0% |
| 2000 Q2 | -5.26 Million USD | -8.74% |
| 2000 Q4 | -4.61 Million USD | -19.14% |
| 1999 FY | -5.51 Million USD | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Thermo Fisher Scientific Inc. | 5.99 Billion USD | 119.366% |
| Dynavax Technologies Corporation | -6.38 Million USD | -18071.858% |
| IQVIA Holdings Inc. | 1.35 Billion USD | 185.493% |
| Biogen Inc. | 1.16 Billion USD | 199.991% |
| Iovance Biotherapeutics, Inc. | -444.03 Million USD | -161.465% |
| Mettler-Toledo International Inc. | 788.77 Million USD | 247.19% |
| Sarepta Therapeutics, Inc. | -535.97 Million USD | -116.614% |
| Supernus Pharmaceuticals, Inc. | 1.31 Million USD | 88321.884% |
| Waters Corporation | 642.23 Million USD | 280.775% |
| Perrigo Company plc | -12.7 Million USD | -9041.732% |
| uniQure N.V. | -308.47 Million USD | -276.364% |
| Agios Pharmaceuticals, Inc. | -352.08 Million USD | -229.747% |
| Amicus Therapeutics, Inc. | -151.58 Million USD | -665.912% |
| Atara Biotherapeutics, Inc. | -276.12 Million USD | -320.46% |
| bluebird bio, Inc. | -211.91 Million USD | -447.866% |
| Cara Therapeutics, Inc. | -118.51 Million USD | -879.639% |
| Imunon, Inc. | -19.51 Million USD | -5849.277% |
| Myriad Genetics, Inc. | -112 Million USD | -936.607% |
| Neurocrine Biosciences, Inc. | 249.7 Million USD | 564.958% |
| Nektar Therapeutics | -276.05 Million USD | -320.567% |
| Editas Medicine, Inc. | -153.21 Million USD | -657.739% |
| Verastem, Inc. | -87.36 Million USD | -1228.877% |
| Walgreens Boots Alliance, Inc. | -8.63 Billion USD | 86.556% |
| Corbus Pharmaceuticals Holdings, Inc. | -44.6 Million USD | -2502.945% |
| Heron Therapeutics, Inc. | -110.55 Million USD | -950.118% |
| Unity Biotechnology, Inc. | -39.86 Million USD | -2812.694% |
| BioMarin Pharmaceutical Inc. | 167.64 Million USD | 792.535% |
| Sangamo Therapeutics, Inc. | -257.83 Million USD | -350.295% |
| Evolus, Inc. | -61.68 Million USD | -1782.143% |
| Adicet Bio, Inc. | -142.65 Million USD | -713.834% |
| Aclaris Therapeutics, Inc. | -88.48 Million USD | -1212.146% |
| Regeneron Pharmaceuticals, Inc. | 3.95 Billion USD | 129.366% |
| Esperion Therapeutics, Inc. | -209.24 Million USD | -454.844% |
| FibroGen, Inc. | -284.23 Million USD | -308.469% |
| Agilent Technologies, Inc. | 1.24 Billion USD | 193.629% |
| OPKO Health, Inc. | -188.86 Million USD | -514.731% |
| Homology Medicines, Inc. | -53.74 Million USD | -2060.281% |
| Geron Corporation | -184.12 Million USD | -530.543% |
| Alnylam Pharmaceuticals, Inc. | -440.24 Million USD | -163.719% |
| Exelixis, Inc. | 207.76 Million USD | 658.804% |
| Viking Therapeutics, Inc. | -85.89 Million USD | -1251.65% |
| Anavex Life Sciences Corp. | -47.5 Million USD | -2343.953% |
| Intellia Therapeutics, Inc. | -481.19 Million USD | -141.276% |
| Zoetis Inc. | 2.34 Billion USD | 149.531% |
| Axsome Therapeutics, Inc. | -239.23 Million USD | -385.291% |
| Abeona Therapeutics Inc. | -54.18 Million USD | -2042.541% |
| Vertex Pharmaceuticals Incorporated | 3.61 Billion USD | 132.075% |
| Kala Pharmaceuticals, Inc. | -42.19 Million USD | -2651.25% |
| Ionis Pharmaceuticals, Inc. | -366.28 Million USD | -216.965% |
| Corcept Therapeutics Incorporated | 106.14 Million USD | 1193.838% |
| Halozyme Therapeutics, Inc. | 281.59 Million USD | 512.296% |
| Blueprint Medicines Corporation | -506.98 Million USD | -129.001% |
| Insmed Incorporated | -749.56 Million USD | -54.889% |
| TG Therapeutics, Inc. | 12.67 Million USD | 9261.932% |
| Incyte Corporation | 597.59 Million USD | 294.277% |
| Emergent BioSolutions Inc. | -760.5 Million USD | -52.663% |